Bioventix (BVXP)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 1,990.00 |
|---|---|
| 52-week range | 1,300.00 – 2,255.00 |
| Return, 1 month / 3 months | +24.4% / +33.6% |
| Return, 1 year / 3 years | +9.4% / −37.8% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 41.7% |
| Worst drawdown (1 year) | -37.5% |
| Average daily value traded | 22.13M GBX |
| Dividend yield | 7.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bioventix makes specialised monoclonal antibodies used in clinical diagnostic testing. Its antibodies are supplied to diagnostic companies that build them into immunoassays for measuring hormones, vitamins, drugs and markers of heart and other conditions in blood samples. The company develops these biological reagents at its own laboratory and licenses and supplies them to customers in the diagnostics industry. Bioventix is based in Farnham, in Surrey, in the United Kingdom.
On this site Bioventix appears as a stock on the London Stock Exchange (UK), code BVXP, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bioventix (BVXP) trades on the London Stock Exchange in UK. It last closed at GBX 1,990.00 on 27 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 922 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 9.4% and over the last three months it rose 33.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.4% | ||
| From 52-week high | -9.5% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 33.6% | ||
| 6-month return | 17.1% | ||
| 12-month return, skipping the last month | -12.0% | ||
| Stability (higher is calmer) | 36 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.5% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 22.13M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 88 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.5% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.2% |
|---|---|
| 1 month | +24.4% |
| 3 months | +33.6% |
| 6 months | +17.1% |
| 1 year | +9.4% |
| 3 years | −37.8% |
| 5 years | −27.5% |
Signals
| 50-day / 200-day average | 1,707.60 / 1,638.79 |
|---|---|
| Golden / death cross (60 days) | Golden, 9 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 141.62 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Apr 2026 | GBP 0.7000 |
| 6 Nov 2025 | GBP 0.8000 |
| 10 Apr 2025 | GBP 0.7000 |
| 7 Nov 2024 | GBP 0.8700 |
| 11 Apr 2024 | GBP 0.6800 |
| 9 Nov 2023 | GBP 0.9000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.